A second shot at PARP1 from Eikon
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
DualityBio tries to float again
The group expects to raise nearly $170m.
Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
